These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12183554)

  • 1. Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
    Schnapp AR; Eickhoff CS; Sizemore D; Curtiss R; Hoft DF
    Infect Immun; 2002 Sep; 70(9):5065-74. PubMed ID: 12183554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
    Schnapp AR; Eickhoff CS; Scharfstein J; Hoft DF
    Microbes Infect; 2002 Jul; 4(8):805-13. PubMed ID: 12270727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.
    Hoft DF; Schnapp AR; Eickhoff CS; Roodman ST
    Infect Immun; 2000 Jan; 68(1):197-204. PubMed ID: 10603388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against
    Antonoglou MB; Sánchez Alberti A; Redolfi DM; Bivona AE; Fernández Lynch MJ; Noli Truant S; Sarratea MB; Iannantuono López LV; Malchiodi EL; Fernández MM
    Front Immunol; 2020; 11():1279. PubMed ID: 32695105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.
    Cazorla SI; Becker PD; Frank FM; Ebensen T; Sartori MJ; Corral RS; Malchiodi EL; Guzmán CA
    Infect Immun; 2008 Jan; 76(1):324-33. PubMed ID: 17967857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
    Cazorla SI; Frank FM; Becker PD; Corral RS; Guzmán CA; Malchiodi EL
    Vaccine; 2008 Apr; 26(16):1999-2009. PubMed ID: 18342408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.
    Hoft DF; Eickhoff CS
    Infect Immun; 2002 Dec; 70(12):6715-25. PubMed ID: 12438346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
    Cazorla SI; Frank FM; Becker PD; Arnaiz M; Mirkin GA; Corral RS; Guzmán CA; Malchiodi EL
    J Infect Dis; 2010 Jul; 202(1):136-44. PubMed ID: 20497050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.
    Bontempi I; Leal K; Prochetto E; Díaz G; Cabrera G; Bortolotti A; Morbidoni HR; Borsuk S; Dellagostin O; Marcipar I
    Clin Exp Immunol; 2020 Sep; 201(3):306-316. PubMed ID: 32464684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII).
    Laderach D; Cerban F; Motran C; Vottero de Cima E; Gea S
    Int J Parasitol; 1996 Nov; 26(11):1249-54. PubMed ID: 9024869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
    Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
    Front Immunol; 2020; 11():565142. PubMed ID: 33162979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice.
    Martinez-Campos V; Martinez-Vega P; Ramirez-Sierra MJ; Rosado-Vallado M; Seid CA; Hudspeth EM; Wei J; Liu Z; Kwityn C; Hammond M; Ortega-López J; Zhan B; Hotez PJ; Bottazzi ME; Dumonteil E
    Vaccine; 2015 Aug; 33(36):4505-12. PubMed ID: 26192358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.
    Matos MN; Cazorla SI; Bivona AE; Morales C; Guzmán CA; Malchiodi EL
    Infect Immun; 2014 Oct; 82(10):4265-75. PubMed ID: 25069980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization of mice with a TolA-like surface protein of Trypanosoma cruzi generates CD4(+) T-cell-dependent parasiticidal activity.
    Quanquin NM; Galaviz C; Fouts DL; Wrightsman RA; Manning JE
    Infect Immun; 1999 Sep; 67(9):4603-12. PubMed ID: 10456906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis and partial epitope mapping of human T cell responses to Trypanosoma cruzi cysteinyl proteinase.
    Arnholdt AC; Piuvezam MR; Russo DM; Lima AP; Pedrosa RC; Reed SG; Scharfstein J
    J Immunol; 1993 Sep; 151(6):3171-9. PubMed ID: 7690795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
    Cerny N; Sánchez Alberti A; Bivona AE; De Marzi MC; Frank FM; Cazorla SI; Malchiodi EL
    Hum Vaccin Immunother; 2016; 12(2):438-50. PubMed ID: 26312947
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
    Front Immunol; 2019; 10():1456. PubMed ID: 31293599
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.
    Garg N; Tarleton RL
    Infect Immun; 2002 Oct; 70(10):5547-55. PubMed ID: 12228281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.